ADC Therapeutics (ADCT) Free Cash Flow (2019 - 2023)
Historic Free Cash Flow for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to -$32.0 million.
- ADC Therapeutics' Free Cash Flow rose 7687.85% to -$32.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$121.9 million, marking a year-over-year increase of 1186.38%. This contributed to the annual value of -$124.7 million for FY2024, which is 229.69% down from last year.
- Latest data reveals that ADC Therapeutics reported Free Cash Flow of -$32.0 million as of Q4 2023, which was up 7687.85% from -$37.3 million recorded in Q3 2023.
- In the past 5 years, ADC Therapeutics' Free Cash Flow registered a high of $2195.0 during Q3 2022, and its lowest value of -$138.2 million during Q4 2022.
- For the 5-year period, ADC Therapeutics' Free Cash Flow averaged around -$20.9 million, with its median value being -$58299.0 (2021).
- In the last 5 years, ADC Therapeutics' Free Cash Flow surged by 10374.65% in 2022 and then tumbled by 170096560.36% in 2023.
- ADC Therapeutics' Free Cash Flow (Quarter) stood at -$33655.0 in 2019, then crashed by 95285.53% to -$32.1 million in 2020, then soared by 99.82% to -$58588.0 in 2021, then plummeted by 235829.38% to -$138.2 million in 2022, then surged by 76.88% to -$32.0 million in 2023.
- Its last three reported values are -$32.0 million in Q4 2023, -$37.3 million for Q3 2023, and -$36.2 million during Q2 2023.